Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anna Zurlo is active.

Publication


Featured researches published by Anna Zurlo.


American Journal of Alzheimers Disease and Other Dementias | 2016

Magnesium Status in Alzheimer’s Disease A Systematic Review

Nicola Veronese; Anna Zurlo; Marco Solmi; Claudio Luchini; Caterina Trevisan; Giulia Bano; Enzo Manzato; Giuseppe Sergi; Ragnar Rylander

The interest in poor magnesium (Mg) status as risk factor for Alzheimer’s disease (AD) is increasing due to its antioxidant and neuroprotective properties. A systematic PubMed literature search of studies investigating Mg status was undertaken comparing AD to healthy controls (HCs) or patients with medical illness (medical controls [MCs]). Standardized mean differences (SMDs) ± 95% confidence intervals (CIs) were calculated for all outcomes. Of 192 potentially eligible studies, 13 were included (559 patients with AD, 381 HCs, and 126 MCs). Compared to HCs, patients with AD had significantly lower Mg in cerebrospinal fluid (2 studies; SMD = −0.35; P = .02) and in hair (2 studies; SMD = −0.75; P = .0001). No differences between AD and controls were evident for serum Mg. In conclusion, AD seems to be associated with a lower Mg status when compared to HCs, while the scarcity of studies limited the findings about MCs.


Nutrition Metabolism and Cardiovascular Diseases | 2016

High serum uric acid levels increase the risk of metabolic syndrome in elderly women: The PRO.V.A study.

Anna Zurlo; Nicola Veronese; Valter Giantin; Monica Maselli; Sabina Zambon; Stefania Maggi; Estella Musacchio; Elena Debora Toffanello; Leonardo Sartori; Egle Perissinotto; Gaetano Crepaldi; Enzo Manzato; G. Sergi

BACKGROUND AND AIMS Serum uric acid (SUA) is the end-product of purine metabolism in humans, and its levels often increase in subjects with metabolic syndrome (MetS). Despite several studies demonstrating a relationship between increased SUA levels and the prevalence of MetS, prospective data on SUA as a predictor of the incidence of MetS in the elderly are limited. Our aim was to conduct a prospective study on the association between SUA concentrations and the onset of MetS in an elderly Italian cohort. METHODS AND RESULTS This is a cohort study (Progetto Veneto Anziani; Pro.V.A.) involving community-dwelling subjects aged ≥65 years and followed up for a mean 4.4 years. We included 1128 participants (aged 74.7 ± 7.1 years) without MetS at the baseline. Gender-specific SUA groups according to the standard deviation (SD) from the mean were considered, taking the incidence of MetS as the main outcome. The mean SUA level was significantly higher in men than in women (5.4 ± 1.2 vs. 4.5 ± 1.2 mg/dl; p < 0.0001). Over the 4.4-year follow-up, 496 individuals developed MetS. After adjusting for potential confounders, Coxs regression analysis revealed no relationship between higher baseline SUA concentrations and the incidence of MetS in men or in the sample as whole, while women with SUA levels more than 1 SD above the mean (≥5.7 mg/dl) carried a 58% higher risk (95%CI: 1.03-2.40; p = 0.03) of being newly diagnosed with MetS during the follow-up. CONCLUSION High SUA levels significantly and independently predicted MetS in older women, but not in men, over a 4.4-year follow-up.


European Journal of Gastroenterology & Hepatology | 2016

Short article: Relapsing Whipple's disease: a case report and literature review.

Elena Ruggiero; Anna Zurlo; Giantin; Francesca Galeazzi; Claudia Mescoli; Giovanni Nante; Florinda Petruzzellis; Enzo Manzato

Whipple’s disease is a rare infection caused by Tropheryma whipplei, a Gram-negative Bacillus usually found in macrophages of the lamina propria of the small intestine. The typical clinical manifestations of classic Whipple’s disease are diarrhea, weight loss, malabsorption, abdominal pain, and arthralgia. The disease’s laboratory diagnosis is currently based on duodenal biopsy. Treatment generally includes primary therapy for 2 weeks with intravenous antibiotics capable of reaching high levels in the cerebrospinal fluid, such as ceftriaxone, usually followed by treatment with oral cotrimoxazole for 1 year. Early diagnosis should enable appropriate treatment and improves the prognosis, and prolonged antibiotic treatment often leads to complete remission. Our case report focuses on a 72-year-old man who had been passing watery stools for 1–2 months, accompanied by low-grade fever. He reported profound asthenia, a weight loss of about 3 kg, and loss of appetite. Thirty years earlier (in 1984), he had been working as a horse keeper at a University Department of Agricultural and Veterinary Studies, where he had contracted Whipple’s disease. Laboratory tests and microbiological studies led to a diagnosis of recurrent Whipple’s disease. Esophagogastroduodenoscopy was performed under deep sedation. Biopsy samples obtained from the stomach and duodenum were stained with hematoxylin and eosin, Giemsa, and periodic acid–Schiff to identify any accumulation of typical periodic acid–Schiff-positive macrophages in the lamina propria. A specific quantitative real-time PCR assay using specific oligonucleotide probes for targeting repeated sequences of Tropheryma whipplei was also performed to detect its DNA in the duodenum samples.


European Journal of Gastroenterology & Hepatology | 2016

Relapsing Whipple's disease: A case report and literature review

Elena Ruggiero; Anna Zurlo; Valter Giantin; Francesca Galeazzi; Claudia Mescoli; Giovanni Nante; Florinda Petruzzellis; Enzo Manzato

Whipple’s disease is a rare infection caused by Tropheryma whipplei, a Gram-negative Bacillus usually found in macrophages of the lamina propria of the small intestine. The typical clinical manifestations of classic Whipple’s disease are diarrhea, weight loss, malabsorption, abdominal pain, and arthralgia. The disease’s laboratory diagnosis is currently based on duodenal biopsy. Treatment generally includes primary therapy for 2 weeks with intravenous antibiotics capable of reaching high levels in the cerebrospinal fluid, such as ceftriaxone, usually followed by treatment with oral cotrimoxazole for 1 year. Early diagnosis should enable appropriate treatment and improves the prognosis, and prolonged antibiotic treatment often leads to complete remission. Our case report focuses on a 72-year-old man who had been passing watery stools for 1–2 months, accompanied by low-grade fever. He reported profound asthenia, a weight loss of about 3 kg, and loss of appetite. Thirty years earlier (in 1984), he had been working as a horse keeper at a University Department of Agricultural and Veterinary Studies, where he had contracted Whipple’s disease. Laboratory tests and microbiological studies led to a diagnosis of recurrent Whipple’s disease. Esophagogastroduodenoscopy was performed under deep sedation. Biopsy samples obtained from the stomach and duodenum were stained with hematoxylin and eosin, Giemsa, and periodic acid–Schiff to identify any accumulation of typical periodic acid–Schiff-positive macrophages in the lamina propria. A specific quantitative real-time PCR assay using specific oligonucleotide probes for targeting repeated sequences of Tropheryma whipplei was also performed to detect its DNA in the duodenum samples.


Aging Clinical and Experimental Research | 2018

Reply to the letter “Could cardiac troponin I levels predict mortality in the elderly?”

Francesca Attanasio; Pamela Carrer; Anna Zurlo; Anna Rossi; Luciano Babuin; Monica Mion; Martina Zaninotto; Mario Plebani; Sabino Iliceto; Enzo Manzato; Valter Giantin

Dear editor, We thank Dr. Aycicek and colleagues [1] for their careful reading of our recently published work [2] in which we assessed factors influencing the increase in cardiac Troponin I (cTnI) and its prognostic value in hospitalized older patients. In our study, we found that cardiovascular diseases (CVD) were statistically more frequent in patients positive on cTnI on admission. This positivity resulted as a mortality risk factor at 6 months after hospital stay. As outlined by the authors, we did not show if CVD were more common in patients who died in comparison with those who survived during the 6-month follow-up. Here we report the results on the prevalence of CVD in these groups of patients, who did not show any significant difference regarding congestive heart failure (23.5 vs. 23.1), coronary heart disease (41.2 vs. 31.1), myocardial infarction (23.5 vs. 14.3), arrhythmia (33.8 vs. 33.6 deceased vs survived patients in all comparisons). Concerning having considered CVD in the regression analyses, we confirm that such comorbidities were taken into account by including in our models the variable “Heart diseases”, defined as the presence of one among the following: congestive heart failure, coronary heart disease, myocardial infarction, arrhythmias or left ventricular hypertrophy. With regard to the time elapsed between the initiation of the symptoms and admission to Emergency Department, this data was not collected and we recognize this as a limit of our study. In conclusion, we thank Dr. Aycicek and colleagues for their accurate comments. We agree with them that further research is needed in the light of these suggestions to assess the real prognostic value of cTnI in older patients.


Geriatrics & Gerontology International | 2017

Advanced dementia: opinions of physicians and nurses about antibiotic therapy, artificial hydration and nutrition in patients with different life expectancies

Valentina Pengo; Anna Zurlo; Alberto Voci; E. Valentini; Francesca De Zaiacomo; Massimo Catarini; Mario Iasevoli; Stefania Maggi; Renzo Pegoraro; Enzo Manzato; Valter Giantin

Aim: The aim of the present study was to investigate the proportion of physicians and nurses who agree with the administration of antibiotic therapy (AT), artificial hydration (AH), and artificial nutrition (AN) in patients with advanced dementia and different life expectancies. Furthermore, we aimed at analyzing the correlates of the opinion according to which medical treatments should no longer be given to advanced dementia patients once their life expectancy falls.


European Journal of Gastroenterology & Hepatology | 2016

Short article: Relapsing Whippleʼs disease

Elena Ruggiero; Anna Zurlo; Valter Giantin; Francesca Galeazzi; Claudia Mescoli; Giovanni Nante; Florinda Petruzzellis; Enzo Manzato

Whipple’s disease is a rare infection caused by Tropheryma whipplei, a Gram-negative Bacillus usually found in macrophages of the lamina propria of the small intestine. The typical clinical manifestations of classic Whipple’s disease are diarrhea, weight loss, malabsorption, abdominal pain, and arthralgia. The disease’s laboratory diagnosis is currently based on duodenal biopsy. Treatment generally includes primary therapy for 2 weeks with intravenous antibiotics capable of reaching high levels in the cerebrospinal fluid, such as ceftriaxone, usually followed by treatment with oral cotrimoxazole for 1 year. Early diagnosis should enable appropriate treatment and improves the prognosis, and prolonged antibiotic treatment often leads to complete remission. Our case report focuses on a 72-year-old man who had been passing watery stools for 1–2 months, accompanied by low-grade fever. He reported profound asthenia, a weight loss of about 3 kg, and loss of appetite. Thirty years earlier (in 1984), he had been working as a horse keeper at a University Department of Agricultural and Veterinary Studies, where he had contracted Whipple’s disease. Laboratory tests and microbiological studies led to a diagnosis of recurrent Whipple’s disease. Esophagogastroduodenoscopy was performed under deep sedation. Biopsy samples obtained from the stomach and duodenum were stained with hematoxylin and eosin, Giemsa, and periodic acid–Schiff to identify any accumulation of typical periodic acid–Schiff-positive macrophages in the lamina propria. A specific quantitative real-time PCR assay using specific oligonucleotide probes for targeting repeated sequences of Tropheryma whipplei was also performed to detect its DNA in the duodenum samples.


Aging Clinical and Experimental Research | 2012

Discussing end-of-life care issues with terminally ill patients and their relatives: comparisons among physicians, nurses and psychologists.

Mario Iasevoli; Giantin; Voci A; E. Valentini; Anna Zurlo; Stefania Maggi; Paola Siviero; G Orru; Gaetano Crepaldi; Renzo Pegoraro; Enzo Manzato


Archives of Gerontology and Geriatrics | 2015

Short- and longer-term predictive capacity of the Multidimensional Prognostic Index: The timing of the assessment is of no consequence

Elisabetta De Luca; Egle Perissinotto; Laura Fabris; Valentina Pengo; Anna Zurlo; Pietro De Toni; Francesca De Zaiacomo; Enzo Manzato; Valter Giantin


Aging Clinical and Experimental Research | 2018

Prognostic value of cardiac troponin I assay in hospitalized elderly patients

Francesca Attanasio; Pamela Carrer; Anna Zurlo; Anna Rossi; Luciano Babuin; Monica Mion; Martina Zaninotto; Mario Plebani; Sabino Iliceto; Enzo Manzato; Valter Giantin

Collaboration


Dive into the Anna Zurlo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stefania Maggi

National Research Council

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge